Cellectis Says European Commission Has Granted An Orphan Drug Designation To Its Product Candidate UCART22 For Treatment Of Acute Lymphoblastic Leukemia

UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in BALLI-01, a Phase 1/2 open-label dose-escalation and dose-expansion study, designed to evaluate the safety, expansion, persistence and clinical activity of UCART22 in patients with relapse/refractory ALL.